Pancreatic Cancer Research

ResearcherAsan Medical CenterActive in the last 2 years

Hyoung Jung Kim

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3391-5621; OpenAlex author ID A5084514767, A5144061522. Sources: OpenAlex.

Their work

Papers
19 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
36
Papers, trials and grants by year

2017: 2 papers · 2018: 2 papers · 2019: 1 paper · 2020: 1 paper · 2021: 4 papers · 2022: 3 papers · 2023: 1 paper · 2024: 3 papers · 2025: 2 papers

Papers 19

  1. Survival Outcomes According to NCCN Criteria for Resection Following Neoadjuvant Therapy for Patients with Localized Pancreatic Cancer. Co-author DOI 10.1245/s10434-024-16437-9↗
  2. ASO Author Reflections: Prognostic Value of NCCN Criteria for Resection Following Neoadjuvant Therapy in Localized Pancreatic Cancer. Co-author DOI 10.1245/s10434-024-16618-6↗
  3. Comparison of the different versions of NCCN guidelines for predicting margin-negative resection of pancreatic cancer in patients undergoing upfront surgery. Co-author DOI 10.1007/s00261-024-04299-4↗
  4. Computed tomography-based vascular burden index as a predictor of vascular resection and pathological vascular invasion in pancreatic cancer with neo-adjuvant … Co-author DOI 10.1016/j.ejso.2024.108494↗
  5. Predicting Recurrence-Free Survival After Upfront Surgery in Resectable Pancreatic Ductal Adenocarcinoma: A Preoperative Risk Score Based on CA 19-9, CT, and 1… Co-author DOI 10.3348/kjr.2023.1235↗
  6. Large Duct Pancreatic Ductal Adenocarcinoma: A Morphological Variant of Pancreatic Ductal Adenocarcinoma With Distinct CT and MRI Characteristics. Co-author DOI 10.3348/kjr.2023.0521↗
  7. Prediction of margin-negative resection of pancreatic ductal adenocarcinoma following neoadjuvant therapy: Diagnostic performance of NCCN criteria for resectio… Co-author DOI 10.1002/jhbp.1192↗
  8. MRI features for differentiation of autoimmune pancreatitis from pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. Last author DOI 10.1016/j.dld.2021.11.013↗
  9. Preoperative data-based deep learning model for predicting postoperative survival in pancreatic cancer patients. Co-author DOI 10.1016/j.ijsu.2022.106851↗
  10. Multiparametric MRI for prediction of treatment response to neoadjuvant FOLFIRINOX therapy in borderline resectable or locally advanced pancreatic cancer. Co-author DOI 10.1007/s00330-020-07134-8↗
  11. CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy. Co-author DOI 10.1007/s00330-020-07188-8↗
  12. Meta-analysis of CT and MRI for differentiation of autoimmune pancreatitis from pancreatic adenocarcinoma. Last author DOI 10.1007/s00330-020-07416-1↗
  13. CT in the prediction of margin-negative resection in pancreatic cancer following neoadjuvant treatment: a systematic review and meta-analysis. Co-author DOI 10.1007/s00330-020-07433-0↗
  14. Estimating Recurrence after Upfront Surgery in Patients with Resectable Pancreatic Ductal Adenocarcinoma by Using Pancreatic CT: Development and Validation of … Co-author DOI 10.1148/radiol.2020200281↗
  15. Differentiating focal autoimmune pancreatitis and pancreatic ductal adenocarcinoma: contrast-enhanced MRI with special emphasis on the arterial phase. Co-author DOI 10.1007/s00330-019-06200-0↗
  16. Comparison of diagnostic performance between CT and MRI in differentiating non-diffuse-type autoimmune pancreatitis from pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00330-018-5565-1↗
  17. Pancreatic Cancer CT: Prediction of Resectability according to NCCN Criteria. Co-author DOI 10.1148/radiol.2018180628↗
  18. DPC4 gene expression in primary pancreatic ductal adenocarcinoma: relationship with CT characteristics. First author DOI 10.1259/bjr.20160403↗
  19. The DPC4/SMAD4 genetic status determines recurrence patterns and treatment outcomes in resected pancreatic ductal adenocarcinoma: A prospective cohort study. Co-author DOI 10.18632/oncotarget.14901↗

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jin Hee Kim · 15 shared papers, 2018–2025 · strength 2.32
  2. Jae Ho Byun · 15 shared papers, 2018–2025 · strength 2.25
  3. Seung Soo Lee · 14 shared papers, 2018–2025 · strength 2.10
  4. Song Cheol Kim · 12 shared papers, 2017–2025 · strength 1.73
  5. Seung‐Mo Hong · 10 shared papers, 2017–2025 · strength 1.52
  6. Dae Wook Hwang · 7 shared papers, 2017–2025 · strength 1.19
  7. Kyu‐pyo Kim · 7 shared papers, 2020–2025 · strength 1.15
  8. Changhoon Yoo · 7 shared papers, 2020–2025 · strength 1.15
  9. Jong Keon Jang · 6 shared papers, 2021–2025 · strength 1.05
  10. Se Jin Choi · 4 shared papers, 2022–2025 · strength 0.79
  11. Dong‐Wan Seo · 4 shared papers, 2021–2025 · strength 0.68
  12. Ki Byung Song · 5 shared papers, 2017–2024 · strength 0.59
  13. Woohyung Lee · 3 shared papers, 2022–2024 · strength 0.54
  14. Sang Hyun Choi · 3 shared papers, 2017–2022 · strength 0.43
  15. Jiyeon Ha · 2 shared papers, 2021–2022 · strength 0.35
  16. Dong Wook Kim · 2 shared papers, 2020–2023 · strength 0.29
  17. Ji Hun Kang · 2 shared papers, 2021 · strength 0.25
  18. Dong Wan Seo · 1 shared paper, 2025 · strength 0.23
  19. Seung Baek Hong · 2 shared papers, 2018–2021 · strength 0.23
  20. Boryeong Jeong · 1 shared paper, 2024 · strength 0.21
  21. Moon-Gyu Lee · 2 shared papers, 2018–2021 · strength 0.20
  22. Eunsung Jun · 2 shared papers, 2017–2022 · strength 0.20
  23. Song Cheol Kim · 1 shared paper, 2024 · strength 0.20
  24. Yejong Park · 1 shared paper, 2024 · strength 0.20
  25. Min Kyu Sung · 1 shared paper, 2024 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.